Lundbeckfonden Ventures — Full Portfolio
12 tracked investments · listed companies and verified rows first
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersDroia VenturesForesite CapitalJazzya Investments+6 more
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRA CapitalAlexandriaArix Bioscience+3 more
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsARCH Venture PartnersSR One Capital ManagementIP GroupWestlake Village BioPartners
Developing a new class of antifungal medicine to overcome limitations of current therapies.
Co-investorsBioBritGolden SeedsKeiretsu ForumPappas CapitalSofinnova Ventures3x5 Partners+4 more
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsJeito CapitalNovo HoldingsInkefRoche Venture Fund
Reneo is an asset and investment management platform for decarbonizing residential real estate portfolios in Germany.
Climate TechEnterprise SoftwarePropTechGermany, DE
Lennart Börner(Founder & Co-CEO)inAlexander Graubner-Müller(Founder & Co-CEO)in
Co-investorsFoundamentalAbingworthAisling CapitalAmzak HealthEurazeoLakestar+4 more
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture PartnersAbingworthAmzak Health+2 more
BiotechCambridge, US
James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)
BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)
Co-investorsAlexandriaLongitude CapitalNew Enterprise Associates (NEA)
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter Reitsma(Founder)inJohn Glasspool(Chief Executive Officer)in
Co-investorsBioGeneration VenturesInkefSound BioventuresYsios CapitalEICEQT Life Sciences+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amplyx PharmaceuticalsKvantify
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.





























